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 ABSTRACT
 Introduction: Recent studies suggest that magnesium deficiency may play a role in inflammation. In diabetes 
and cardio-vascular diseases, conditions with a component of chronic inflammation, C–reactive protein levels 
are higher and associated with low serum magnesium. The objective of this study is to evaluate serum mag-
nesium levels in patients with systemic lupus erythematosus and its potential association with inflammation 
and renal manifestations. Methods: All patients with systemic lupus erythematosus followed in a Systemic 
Immune Diseases Unit, from January 2012 until January 2014, were included in this cross sectional analysis. 
Patients with infection, neoplasia, liver failure and chronic kidney disease (stage > 3) were excluded. Clinical 
information and laboratory results (serum magnesium, C-reactive protein, erythrocyte sedimentation rate, serum 
creatinine and spot urine test) were collected. A multivariate analysis was performed to explore possible predic-
tive factors for hypomagnesaemia. Results: One hundred and two patients were included (94.1% female, 21-86 
years). 33.4% had hypertension, 8.8% had diabetes and 20.6% had hypomagnesaemia (< 1.8mg/dL). There were 
no significant differences between the inflammatory parameters of patients with hypomagnesaemia or normo-
magnesaemia. Serum magnesium was significantly lower with increasing comorbidities (p = 0.01). Leukocyturia 
was significantly higher in the hypomagnesaemia group (p = 0.03) and haematuria had a negative correlation 
with serum magnesium (-0.23, p < 0.05). Multivariate analysis showed that patients with hypertension and 
diabetes had higher risk of hypomagnesaemia: OR 42.29 (95% CI, 1.43-1249.31). Leukocyturia was also indi-
vidually and independently associated with hypomagnesaemia: OR 8.37 (95% CI, 1.40-49.97). Conclusion: The 
presence of hypomagnesaemia in our patients with systemic lupus erythematosus was high. There was no 
association between the levels of serum magnesium and the inflammatory parameters. Increasing comorbidities 
and leukocyturia were independent predictors of lower serum magnesium. Finally, the association of leukocyturia 
and haematuria with lower serum magnesium may suggest a relationship with a higher disease activity.
Key-Words: Inflammation; magnesium deficiency; systemic lupus erythematosus.
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 INTRODUCTION
Experimental evidence suggests that magnesium 
deficiency may play a role in inflammation, although 
its specific interference with the inflammatory 
response is not fully elucidated1-3.
Magnesium has several actions that could explain 
its anti-inflammatory activity: it is a mild physiologic 
calcium blocker that decreases intracellular calcium 
level, blocks sodium attachment to vascular smooth 
muscle cells, increases the vasodilator prostaglandin 
E1, increases nitric oxide, reduces angiotensin-induced 
aldosterone synthesis, reduces triglycerides and 
increases high-density lipoprotein, through an increase 
in lipoprotein lipase activity and by inhibiting HMGCoA 
reductase. Most of these cardiovascular and oxidative 
effects could explain the higher inflammatory state 
seen in states of magnesium deficiency1-4.
In animal models, magnesium deficiency leads to 
pro-inflammatory responses characterised by 
elevations of C-reactive protein (CRP) and nuclear 
factor kappa B, by leukocyte and macrophage activa-
tion, platelet aggregation and endothelial prolifera-
tion; all due to up-regulation of pro-inflammatory 
cytokines1,4,5.
Magnesium deficiency is present in 13.5 to 47.7% 
of patients with type 2 diabetes and is associated 
with the development of insulin resistance and inad-
equate metabolic control6-9. In addition, patients with 
diabetes have higher levels of CRP reflecting higher 
levels of chronic inflammation10. The association of 
hypomagnesaemia with chronic inflammatory diseases 
has also been described in metabolic syndrome, 
hypertension, atherosclerosis and cardiovascular dis-
ease11-13. Deficient magnesium intake and low serum 
magnesium levels have been associated with elevated 
CRP, a widely used indicator of inflammation14,15.
Systemic lupus erythematosus (SLE) is a systemic 
autoimmune disease with multiorgan inflammation, 
characterized by a global loss of self-tolerance with 
 RESUMO
Introdução: Estudos recentes sugerem uma relação entre inflamação e défice de magnésio. Em doenças 
com inflamação crónica, como a diabetes e doenças cárdio-vasculares, os níveis séricos de proteína C-reativa 
são mais altos e associados a menores níveis séricos de magnésio. O objetivo desde trabalho é avaliar o 
magnésio sérico em doentes com lúpus eritematoso sistémico e a sua associação com inflamação e mani-
festações renais. Métodos: Foram incluídos neste estudo transversal, doentes com lúpus eritematoso sis-
témico, seguidos numa unidade de doenças imunomediadas sistémicas, entre Janeiro 2012 e Janeiro 2014. 
Foram excluídos os doentes com infeção, neoplasia, insuficiência hepática e doença renal crónica (estadio 
> 3). Foi colhida informação clínica e laboratorial (magnésio sérico, proteína C-reativa, velocidade de sedi-
mentação, creatinina sérica e exame sumário de urina). Foi usada uma análise multivariada para explorar 
possíveis fatores preditivos de hipomagnesémia. Resultados: Foram incluídos 102 doentes (94.1% do sexo 
feminino, 21-86 anos), 33.4% com hipertensão, 8.8% com diabetes e 20.6% com hipomagnesémia (< 1.8mg/
dL). Não houve diferenças significativas nos parâmetros inflamatórios entre os doentes com hipomagnesémia 
e normomagnesémia. Os valores de magnésio foram mais baixos nos doentes com mais comorbilidades 
associadas (p = 0.01). A leucocitúria foi significativamente maior no grupo com hipomagnesémia (p = 0.03) 
e a hematúria correlacionou-se negativamente com o magnésio sérico (r = -0.23, p < 0.05). Na análise 
multivariada, doentes com hipertensão e diabetes apresentaram maior risco de hipomagnesemia: OR 42.29 
(95% CI, 1.43-1249.31). A leucocitúria foi individualmente e independentemente associada a hipomagnesemia 
OR 8.37 (95% CI, 1.40-49.97). Conclusão: A presença de hipomagnesémia nos nossos doentes com lúpus 
eritematoso sistémico foi elevada. Não encontrámos associação entre os níveis de magnésio sérico e os 
parâmetros inflamatórios. A comorbilidade crescente e a leucocitúria foram preditores independentes de 
hipomagnesémia. A associação de leucocitúria e hematúria com magnésio sérico mais baixo pode sugerir 
uma relação com maior atividade da doença.
Palavras-Chave:  Deficiência magnésio; inflamação; lúpus eritematoso sistémico.
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activation of autoreactive T and B cells, that leads 
to the production of pathogenic autoantibodies and 
tissue injury16. Elevated CRP (although at low levels) 
and raised erythrocyte sedimentation rate (ESR) are 
usually associated with clinically active disease mea-
sured by the SLEDAI score17,18. SLE patients with 
elevation of inflammatory markers (CRP and ESR) 
are also at higher risk of death19.
Magnesium deficiency has been described in 
patients with SLE but the association to inflammation 
has not been studied20. In SLE, a chronic inflamma-
tory disease, low serum magnesium levels may be 
linked to inflammation. Low serum magnesium could 
also be associated with greater disease activity, par-
ticularly with renal manifestations.
The objective of this study is to evaluate the 
association of serum magnesium levels with the 
degree of inflammation (as evaluated by CRP and 
ESR) and renal manifestations [evaluated with esti-
mated glomerular filtration rate (eGFR) and urinalysis] 
in patients with SLE.
 SUBJECTS AND METHODS
Patients fulfilling the American College of Rheu-
matology criteria for SLE21, followed in the Systemic 
Immune-mediated Diseases Unit at our Hospital, from 
January 2012 until January 2014, were included in 
this cross sectional analysis. The patients were evalu-
ated by the attending physician in the outpatient 
clinic and blood sample analyses were performed 
up to one month before. The blood sample analysis 
elected for each patient included at least the deter-
mination of serum magnesium, ESR and CRP (giving 
preference to the set of values with lower CRP). 
When it was not evaluated in the same analysis, the 
serum creatinine (SCr) value was included with a 
maximum interval of one month. The eGFR was cal-
culated using the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) formula22. Patients with 
concomitant infection, neoplasia, liver failure and 
chronic kidney disease (CKD) in stages 4 and 5 
according to K/DOQI 2002 classification (eGFR < 30 
mL/min/1.73m2)23 were excluded.
Clinical information collected included: age, gen-
der, presence of hypertension and diabetes, and 
current therapy [including steroids, other immunosup-
pressive drugs, diuretics and proton pump inhibitors 
(PPI)]. Laboratory results included: serum magnesium 
mg/dL, CRP mg/dL, ESR mm/h, SCr mg/dL and a spot 
urine test (when available).
The spot urine test is a semi-quantitative analysis 
that includes the following ranges: proteinuria – nega-
tive, 50mg/dL, 100mg/dL, 200 mg/dL, 300 mg/dL, 
400 mg/dL; haematuria (quantification of heme con-
centration) – negative, 1+ (0.06mg/dL), 2+ (0.2mg/
dL) and 3+ (1mg/dL); leukocyturia (quantification of 
leukocyte esterase concentration) – negative, 25 UI/L, 
75 UI/L, 250 UI/L, 500 UI/L.
Hypomagnesaemia was defined as serum magne-
sium less than 1.8 mg/dL and patients were divided 
in two groups accordingly: hypomagnesaemia and 
normomagnesaemia. Patients were also divided 
according to the presence of comorbidities: without 
hypertension and diabetes, with hypertension and 
with hypertension and diabetes.
The CRP and ESR values were considered indirect 
indicators of inflammation and renal disease was 
evaluated with eGFR, proteinuria, haematuria and 
leukocyturia.
Statistical analysis was performed using IBM SPSS 
Statistics 20 for Windows. Comparisons between groups 
were performed using chi-square for qualitative vari-
ables and Mann-Whitney and Kruskal-Wallis tests for 
non-parametric continuous variables. To explore the 
association between serum magnesium and the differ-
ent variables, the Spearman correlation factor was 
calculated. A multivariate analysis was also performed 
to explore possible predictive factors of low serum 
magnesium, controlling for the potential confounders. 
The results were considered significant if p < 0.05.
 RESULTS
One hundred and two patients were included 
(94.1% women), with ages ranging from 21 to 86 
years. Hypertension was present in 33.4%, diabetes 
in 8.8% and CKD stage 3 in 14.7% of all patients. 
Hypomagnesaemia was present in 20.6% of all 
patients and in 15.2% of patients without hyperten-
sion or diabetes.
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Table I
Clinical and biologic characteristics of SLE patients according to magnesium serum level
Hypomagnesaemia Normomagnesaemia p value
Age (years) 51.0 (35.5 – 68.0)
(n = 21)
46.0 (33.0 – 53.0)
(n = 81)
0.15
Gender
Female
Male
19 (90.5%)
2 (9.5%)
(n = 21)
77 (95.1%)
4 (4.9%)
(n = 81)
NA
Hypertension 11 (52.4%)
(n = 21)
22 (27.2%)
(n = 81)
0.03
Diabetes 4 (19.0%)
(n = 21)
5 (6.2%)
(n = 81)
0.06
Therapy
Steroids
Prednisolone (mg)
Hydroxychloroquine
Immunosuppressive
Diuretics
PPIs
11 (61.1%)
(n = 18)
5 (0 – 6.3)
(n = 18)
12 (63.2%)
(n = 19)
6 (33.3%)
(n = 18)
3 (17.6%)
(n=17)
10 (58.8%)
(n = 17)
47 (59.5%)
(n = 79)
5 (0 – 7.5)
(n = 79)
49 (62.0%)
(n = 79)
32 (42.1%)
(n = 76)
8 (11.3%)
(n=71)
31 (23.7%)
(n = 71)
0.90
0.78
0.93
0.50
0.48
0.26
Inflammatory parameters
ESR (mm/h)
CRP (mg/dL)
25.0 (11.5 – 48.0)
(n = 21)
0.15 (0.15 – 1.07)
(n = 21)
20.0 (10.0 – 35.5)
(n = 81)
0.15 (0.15 – 0.53)
(n = 81)
0.28
0.58
Renal function
eGFR (mL/min/1.73 m2)
CKD stage 3 (%)
85.8 ± 30.9
(n = 21)
6 (28.6%)
(n = 21)
96,0 ± 23.7
(n = 81)
9 (11.1%)
(n = 81)
0.17
0.08
Spot Urine
Proteinuria (mg/dL)
Haematuria
negative
1+
2+
Leukocyturia (UI/L)
0 (0 – 50)
(n = 16)
13 (81.2%)
2 (12.5%)
1 (6.2%)
(n = 16)
25 (0 – 75)
(n = 16)
0 (0 – 0)
(n = 65)
59 (90.8%)
4 (6.2%)
2 (3.1%)
(n = 65)
0 (0 – 25)
(n = 65)
0.13
NA
0.03
Hypomagnesaemia was defined as SMg < 1,8mg/dL. Haematuria was evaluated with the quantification of heme concentration – negative, 1+ (0.06mg/dL), 2+ (0.2mg/dL) and 3+ 
(1mg/dL). Results are expressed as number (percentage) of individuals for categorical variables or median (Q1 – Q3) for non-parametric continuous variables. Comparisons were 
performed using the Chi-squared test for categorical variables, Mann-Whitney for non-parametric quantitative variables and student’s t-test for parametric quantitative variables. 
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NA, not available for statistical analysis; PPI, proton pump inhibitors; CKD stage 3, chronic kidney disease stage 3 
(according to K/DOQI 2002 classification – eGFR 30-59 mL/min/1.73m2)23
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There were no significant differences between the 
hypomagnesaemia and normomagnesaemia groups 
concerning age, diabetes, eGFR, CKD stage 3, type 
of immunosuppressive therapy, diuretic or PPI use. 
There were no differences regarding ESR or CRP 
levels (Table I).
Magnesium – association with inflammation and renal disease in systemic lupus erythematosus
Table II
Characteristics of SLE patients according to comorbidities
Without hypertension/diabetes Hypertension Hypertension + Diabetes p value
Age (years) 38.0 (31.0 – 51.0)
(n = 66)
53.0 (47.0 – 66.0)
(n = 27)
73.5 (65.5 – 78.5)
(n = 6)
<0.0001
Gender
Female
Male
62 (93.9%)
4 (6.1%)
(n = 66)
26 (96.3%)
1 (3.7%)
(n = 27)
6 (100%)
–
(n = 6)
NA
SMg (mg/dL) 1.95 (1.8 – 2.1)
(n = 66)
1.9 (1.7 – 2.0)
(n = 27)
1.6 (1.4 – 1.9)
(n = 6)
0.01
Inflammatory parameters
ESR (mm/h)
CRP (mg/dL)
21.5 (8.8 – 35.8)
(n = 66)
0.2 (0.2 – 0.3)
(n = 66)
20.0 (13.0 – 43.0)
(n = 27)
0.3 (0.2 – 0.8)
(n=27)
42.0 (22.8 – 52.0)
(n = 6)
1.3 (0.9 – 3.6)
(n=6)
0.15
0.003
Therapy
Steroids
Prednisolone (mg)
Hydroxychloroquine
Immunosuppressive
Diuretics
PPIs
35 (55.6%)
(n = 63)
2.5 (0 – 5.0)
(n = 63)
38 (59.4%)
(n = 64)
25 (40.3%)
(n = 62)
3 (5.3%)
(n = 57)
26 (45.6%)
(n = 57)
18 (69.2%)
(n = 26)
5.0 (0 – 11.3)
(n = 26)
20 (80.0%)
(n = 25)
8 (33.3%)
(n = 24)
7 (30.4%)
(n = 23)
11 (47.8%)
(n = 23)
4 (80.0%)
(n = 5)
20.0 (2.5 – 20.0)
(n = 5)
2 (33.3%)
(n = 6)
3 (60.0%)
(n = 5)
1 (20.0%)
(n = 5)
2 (40.0%)
(n = 5)
NA
0.04
NA
NA
NA
NA
Renal function
eGFR (mL/min/1.73 m2)
CKD stage 3 (%)
101.2 ± 22.9
(n = 66)
5 (7.6%)
(n = 66)
82.6 ± 21.1
(n = 27)
6 (22.2%)
(n = 27)
68.3 ± 20.8
(n = 6)
3 (50.0%)
(n = 6)
<0,001
NA
Urine Spot
Proteinuria (mg/dL)
Haematuria
negative
1+
2+
Leukocyturia (UI/L)
0 (0 – 0)
(n = 54)
50 (92.6%)
3 (5.6%)
1 (1.9%)
(n = 54)
0 (0 – 25.0)
(n = 54)
0 (0 – 0)
(n = 20)
16 (80.0%)
2 (10.0%)
2 (10.0%)
(n = 20)
0 (0 – 25.0)
(n = 20)
25.0 (0 – 237.5)
(n = 4)
4 (100%)
–
–
(n = 4)
12.5 (0 – 193.8)
(n = 4)
0.20
NA
0.85
Haematuria was evaluated with the quantification of heme concentration – negative, 1+ (0.06mg/dL), 2+ (0.2mg/dL) and 3+ (1mg/dL). Results are expressed as number (percentage) 
of individuals for categorical variables or median (Q1 – Q3) for non-parametric continuous variables. Comparisons were performed using the Chi-squared test for categorical 
variables, Kruskal-Wallis for non-parametric continuous variables and ANOVA for parametric quantitative variables. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
NA, not available for statistical analysis; PPI, proton pump inhibitors; SLE, systemic lupus erythematosus; SMg, serum magnesium; CKD stage 3, chronic kidney disease stage 3 
(according to K/DOQI 2002 classification – eGFR 30-59 mL/min/1.73m2)23.
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There was a significant difference between the 
two groups in relation to hypertension, with the 
hypomagnesaemia group having a higher percentage 
of patients with hypertension (52.4% versus 27.2%, 
p = 0.03). The same trend was observed between 
groups concerning diabetes (p = 0.06), (Table I).
In addition, 44.4% of patients with diabetes and 
66.7% of patients with hypertension and diabetes 
had hypomagnesaemia. Leukocyturia was signifi-
cantly higher in the hypomagnesaemia group (p = 
0.03), (Table I).
When patients were classified according to the 
presence of comorbidities, C-reactive protein was 
significantly higher and serum magnesium was sig-
nificantly lower in the group with more comorbidities 
(p = 0.003 and p = 0.01, respectively) (Table II). 
In addition, the prednisolone dose was significantly 
higher in the hypertension+diabetes group (p = 
0.04). Concerning renal function, eGFR was signifi-
cantly lower with increased comorbidities (p < 0.001). 
There were no significant differences between 
groups concerning ESR, proteinuria and leukocyturia 
(Table II).
Spearman analysis showed a slight negative cor-
relation between serum magnesium and increased 
comorbidities (-0.26, p < 0.05) (Table III). Despite a 
negative correlation between serum magnesium and 
haematuria (-0.23, p < 0.05), increased comorbidities 
were not correlated with haematuria (0.12, p = 0.275). 
No significant correlations were found between serum 
magnesium and ESR, CRP, eGFR, proteinuria or leu-
kocyturia (Table III).
A multivariate analysis was performed to assess 
possible predictive factors for hypomagnesaemia 
(Table IV). Patients with hypertension+diabetes had 
a higher risk of hypomagnesaemia: OR 42.29 (95% 
CI 1.43-1249.31). Leukocyturia was also independently 
associated with hypomagnesaemia: OR 8.37 (95% 
CI 1.4 – 49.97). These results were controlled for 
confounding variables, such as age, gender, hyper-
tension, diabetes, eGFR, CRP levels, haematuria and 
diuretic, PPI and prednisolone therapy. Haematuria 
was not found to be associated with hypomagne-
saemia in the same model.
 DISCUSSION
In our study hypomagnesaemia was frequent 
among SLE patients (20.6% of all patients), when 
comparing with general population. The prevalence 
of hypomagnesaemia in the general population range 
between 2.4% (American population between 55 and 
64 years old) and 14.5% (unselected population 
group in Germany)24,25.
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Table IV
Multivariate analysis – Factors independently and individually associated 
with hypomagnesemia (<1.8mg/dL)
Increasing comorbidities1
Without hypertension/
diabetes OR (95% CI)
Hypertension 
OR (95% CI)
Hypertension + Diabetes 
OR (95% CI)
1 (ref.) 1.96 (0.66 – 5.84)ns 11.20 (1.80 – 69.53)*
1 (ref.) 4.15 (0.75 – 22.93)ns 42.29 (1.43 – 1249.31)*
Leukocyturia2
No OR (95% CI) Yes OR (95% CI)
1 (ref.) 8.37 (1.40-49.97)*
Results expressed as odds ratio (95% confidence interval). CI, confidence interval; NS, 
not statistically significant; OR, odds ratio; SLE, Systemic Lupus Erythematosus; * <0,05.
1 model controlled for age, gender, C-reactive protein values, renal function as esti-
mated glomerular filtration rate, diuretic and proton pump inhibitors therapy and 
prednisolone dose.
2 model controlled for age, gender, C-reactive protein values, renal function as esti-
mated glomerular filtration rate, diuretic and proton pump inhibitors therapy, pred-
nisolone dose, diabetes, hypertension and hematuria (yes/no).
Table III
Spearman correlations
SMg
Age (years) -0.11ns
Increasing comorbidities -0.26*
Therapy
 Steroids 0.02ns
 Prednisolone (mg) -0.06ns
 Hydroxychloroquine -0.01ns
 Immunosuppressive -0.03ns
Diuretics 0.02ns
PPIs 0.01ns
ESR (mm/h) -0.07ns
CRP (mg/dL) -0.09ns
eGFR (mL/min/1.73m2)
Urine Spot
0.04ns
 Proteinuria -0.17ns
 Haematuria -0.23*
 Leukocyturia -0.7ns
NA, not available for statistical analysis; NS, not statistically significant; *, p < 0.05. 
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SMg, serum magnesium; 
PPIs, proton pump inibitors; eGFR, estimated glomerular filtration rate; CKD, chronic 
kidney disease.
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We hypothesised that the association of hypo-
magnesaemia with chronic inflammatory diseases 
should also be found in SLE. Lower serum magnesium 
could correlate with markers of inflammation, like 
CRP and ESR, which in turn correlate with disease 
activity in SLE patients17,18. However, we did not 
find a relationship between lower SMg and higher 
CRP or ESR. A possible explanation could be the 
non-inclusion of clinical variables that could better 
reflect disease activity and inflammation. The use of 
scales that measure disease activity incorporating 
clinical data, such as the SLEDAI score, could estab-
lish a clearer link between inflammation and mag-
nesium. The variables that we used to quantify 
inflammation (CRP and ESR) are also elevated in 
other clinical conditions, despite the major causes 
that have been excluded (neoplasia and infection).
In addition, serum magnesium concentration may 
not accurately reflect the total magnesium status. 
Extracellular magnesium corresponds to 1% of the 
total body magnesium content, skeleton to 60% and 
intracellular to 39%. Serum magnesium only repre-
sents 0.3% of total magnesium. Normal serum mag-
nesium concentration is maintained within normal 
range through regulation by kidneys, gastrointestinal 
tract and bone 26,27. In the early stages of magnesium 
depletion, blood magnesium concentration may still 
be within the normal range, whereas the concentra-
tion in urine may be significantly reduced27. In the 
PREVEND study, the authors did not find any asso-
ciation between serum magnesium and ischaemic 
heart disease but low urinary magnesium excretion 
was independently associated with a higher risk sug-
gesting that urinary magnesium excretion may be a 
more useful marker of magnesium balance28,29.
In the early stages of CKD, the increase of mag-
nesium excretion compensates the loss of renal func-
tion and serum levels are maintained in the normal 
range. If renal function deteriorates further (less than 
30ml/min of creatinine clearance) excretion of mag-
nesium tends to decrease26. Therefore, patients with 
CKD stages 4 and 5 were excluded from this analysis. 
Additionally, low serum magnesium has been associ-
ated with the decline in kidney function in CKD 
patients independently from hypertension, diabetes 
and diuretic use30,31. Fractional magnesium excretion 
seems to be a sensitive parameter to detect tubulo-
interstitial damage even before changes in the renal 
function occur32,33. Therefore, the evaluation of 
magnesium status in our study could be limited and 
the inclusion of urinary magnesium excretion could 
better reflect this subject.
Low serum magnesium has been associated with 
numerous conditions characterised by a chronic 
inflammatory status. Hypertension and diabetes have 
already been associated with hypomagnesaemia in 
several studies and higher SMg seems to be protec-
tive in cardiovascular diseases9,34,35. In our study, 
low serum magnesium was independently associated 
to hypertension and diabetes, regardless of CRP, 
diuretic therapy, prednisolone dose and eGFR.
The use of diuretics, in particular loop diuretics, 
increases the urinary excretion of magnesium36 but 
their use was not associated with lower serum mag-
nesium. Steroids are one of the most commonly 
used drugs to treat SLE but come with an expensive 
price in terms of side effects and long-term complica-
tions and their use in high doses for a significant 
period of time is associated with an increased car-
diovascular risk37. We found that patients with hyper-
tension and diabetes were taking higher daily dos-
ages of prednisolone, but steroids therapy did not 
seem to influence serum magnesium. It seems that 
the presence of hypertension and diabetes influences 
serum magnesium, regardless of whether those 
comorbidities were a consequence of long-term ste-
roid treatment.
Despite the influence of renal function in the regu-
lation of serum magnesium, we did not find any 
association between eGFR and serum magnesium. 
Additionally, eGFR did not influence the association 
of hypertension and diabetes with hypomagnesae-
mia, as already described.
Although we found an association between low 
serum magnesium and hypertension and diabetes, there 
is still a high percentage (15%) of patients with hypo-
magnesaemia not accounted for those comorbidities.
In the multivariate analysis, leukocyturia was found 
to be an independent predictor of lower serum mag-
nesium. Leukocyturia was related to lower serum 
magnesium, regardless of eGFR, hypertension or 
diabetes. In addition, haematuria had a negative 
correlation with serum magnesium that appears not 
to be related to an increased number of comorbidi-
ties. Isolated haematuria and isolated pyuria are 
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associated with active renal and non-renal disease 
in SLE patients38. Therefore, if haematuria and leu-
kocyturia may represent higher SLE activity and lower 
serum magnesium is associated to inflammation in 
several diseases4-15, the association of low serum 
magnesium to haematuria and leukocyturia, may 
suggest that patients with lower levels of serum 
magnesium have higher (renal) disease activity. Fur-
thermore, elevated urine magnesium excretion has 
been correlated with the magnitude of tubulo-inter-
stitial fibrosis in glomerulonephropathies like lupus 
nephritis, although the correlation with serum mag-
nesium and spot urine was not performed 39.
In addition, there were other limitations to point 
out in our study. The small sample size may hinder 
a more robust analysis of the results and the cross-
sectional nature of the study does not allow estab-
lishing causality (and, therefore, whether hypomag-
nesaemia is cause or consequence of inflammation). 
We could not confirm the absence of infection (or 
colonization) in all patients with leukocyturia.
Nevertheless, the recognition that serum magne-
sium is lower in a significant proportion of lupus 
patients should help promoting further investigation 
on this subject.
 CONCLUSION
The presence of hypomagnesaemia in patients with 
SLE is high, especially when hypertension and diabetes 
are present. Nevertheless, we did not find an association 
between lower levels of serum magnesium and CRP or 
ESR. Increasing comorbidities and the presence of leu-
kocyturia were independent predictors of lower serum 
magnesium. Finally, the association of lower serum 
magnesium levels with leukocyturia and haematuria may 
suggest a relationship with higher disease activity.
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